Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
56 hedge funds and large institutions have $241M invested in Third Harmonic Bio in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
39% more capital invested
Capital invested by funds: $173M → $241M (+$68M)
17% more funds holding
Funds holding: 48 → 56 (+8)
4.24% more ownership
Funds ownership: 89.35% → 93.59% (+4.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$10.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.88M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.46M |
| 4 |
CC
Commodore Capital
New York
|
+$4.32M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$13.4M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$3.08M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$306K |
| 4 |
Morgan Stanley
New York
|
-$163K |
| 5 |
Goldman Sachs
New York
|
-$79.2K |
THRD Hedge Fund Activity: Q3 2023 in Review
56 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q3 2023, worth a combined $241M — up 39% from $173M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new THRD positions and 3 closed out — a net gain of 8 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $10.1M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $13.4M sold.
- 56 institutional investors held Third Harmonic Bio (THRD) as of Q3 2023, up from 48 in Q2 2023.
- Funds reported $241M of Third Harmonic Bio stock for Q3 2023, up 39% quarter-over-quarter.
- 11 funds opened new Third Harmonic Bio positions in Q3 2023 and 3 closed out, a net change of +8 holders.
- The largest Third Harmonic Bio buyer in Q3 2023 was Braidwell, an estimated $10.1M added.
- The largest Third Harmonic Bio seller in Q3 2023 was Stonepine Capital Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2023.